MX366375B - Moleculas de administracion selectiva y metodos de uso. - Google Patents
Moleculas de administracion selectiva y metodos de uso.Info
- Publication number
- MX366375B MX366375B MX2015009858A MX2015009858A MX366375B MX 366375 B MX366375 B MX 366375B MX 2015009858 A MX2015009858 A MX 2015009858A MX 2015009858 A MX2015009858 A MX 2015009858A MX 366375 B MX366375 B MX 366375B
- Authority
- MX
- Mexico
- Prior art keywords
- selective delivery
- methods
- delivery molecules
- tissue retention
- sequence
- Prior art date
Links
- 230000014759 maintenance of location Effects 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Radiology & Medical Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Paper (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758680P | 2013-01-30 | 2013-01-30 | |
| PCT/US2014/013942 WO2014120974A1 (en) | 2013-01-30 | 2014-01-30 | Selective delivery molecules and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015009858A MX2015009858A (es) | 2016-02-16 |
| MX366375B true MX366375B (es) | 2019-07-05 |
Family
ID=51262954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009858A MX366375B (es) | 2013-01-30 | 2014-01-30 | Moleculas de administracion selectiva y metodos de uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9782498B2 (enExample) |
| EP (1) | EP2951210A4 (enExample) |
| JP (1) | JP6508781B2 (enExample) |
| KR (2) | KR102278630B1 (enExample) |
| CN (1) | CN105102484B (enExample) |
| AU (1) | AU2014212308B2 (enExample) |
| CA (2) | CA2899448C (enExample) |
| EA (1) | EA031930B1 (enExample) |
| HK (1) | HK1217720A1 (enExample) |
| MX (1) | MX366375B (enExample) |
| WO (1) | WO2014120974A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4032538A3 (en) | 2009-03-02 | 2022-10-26 | Massachusetts Institute of Technology | Methods and products for in vivo enzyme profiling |
| ES2881535T3 (es) | 2011-03-15 | 2021-11-29 | Massachusetts Inst Technology | Detección multiplexada con indicadores codificados con isótopos |
| CN103874512B (zh) | 2011-07-29 | 2016-11-16 | 艾维拉斯生物科学公司 | 选择性递送分子及使用方法 |
| CN105102484B (zh) | 2013-01-30 | 2020-03-10 | 艾维拉斯生物科学公司 | 选择性递送分子及使用方法 |
| JP6847660B2 (ja) | 2013-06-07 | 2021-03-24 | マサチューセッツ インスティテュート オブ テクノロジー | リガンドをコードする合成バイオマーカーのアフィニティベースの検出 |
| ES2992591T3 (en) | 2015-08-18 | 2024-12-16 | Rakuten Medical Inc | Compositions, combinations and related methods for photoimmunotherapy |
| ES2999358T3 (en) | 2015-08-18 | 2025-02-25 | Rakuten Medical Inc | Phthalocyanine dye conjugates and their storage |
| SMT202000649T1 (it) | 2015-11-23 | 2021-01-05 | Bristol Myers Squibb Co | Sistemi di additivi per l'uso nella pegilazione di proteine |
| EP3440013A4 (en) | 2016-04-08 | 2021-03-17 | Massachusetts Institute of Technology | METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES |
| WO2017193070A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| WO2019204363A2 (en) * | 2018-04-16 | 2019-10-24 | Avelas Biosciences, Inc. | Selective delivery of therapeutic and imaging agents |
| WO2019232478A1 (en) | 2018-06-01 | 2019-12-05 | Rakuten Medical, Inc. | Phthalocyanine dye conjugate compositions |
| EP3856921B1 (en) | 2018-09-25 | 2026-04-29 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| US12704501B2 (en) | 2019-03-29 | 2026-08-11 | Rakuten Medical, Inc. | Methods for photoimmunotherapy and related biomarkers |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452720A (en) | 1980-06-04 | 1984-06-05 | Teijin Limited | Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element |
| US4439356A (en) | 1981-03-03 | 1984-03-27 | Syva Company | Unsymmetrical fluorescein derivatives |
| US4496542A (en) | 1981-03-30 | 1985-01-29 | Usv Pharmaceutical Corporation | N-substituted-amido-amino acids |
| US4507389A (en) | 1982-12-16 | 1985-03-26 | Monsanto Company | Determination of collagenase by reacting with peptide substrates |
| US4466919A (en) | 1982-12-16 | 1984-08-21 | Monsanto Company | Peptide substrates for mammalian collagenase |
| US5330900A (en) | 1987-12-31 | 1994-07-19 | Tropix, Inc. | Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes |
| US5066580A (en) | 1988-08-31 | 1991-11-19 | Becton Dickinson And Company | Xanthene dyes that emit to the red of fluorescein |
| GB8927722D0 (en) | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5227487A (en) | 1990-04-16 | 1993-07-13 | Molecular Probes, Inc. | Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes |
| US5750409A (en) | 1991-11-18 | 1998-05-12 | Boehringer Mannheim Gmbh | Pentacyclic compounds and their use as absorption or fluorescent dyes |
| DE69628731T3 (de) | 1995-11-01 | 2012-09-20 | Bracco Suisse S.A. | Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel |
| US5847162A (en) | 1996-06-27 | 1998-12-08 | The Perkin Elmer Corporation | 4, 7-Dichlororhodamine dyes |
| US6080852A (en) | 1996-06-27 | 2000-06-27 | The Perkin-Elmer Corporation | 4,7-dichlororhodamine dyes |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| GB9708265D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6008379A (en) | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
| US5936087A (en) | 1997-11-25 | 1999-08-10 | The Perkin-Elmer Corporation | Dibenzorhodamine dyes |
| US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
| US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
| JP2002518521A (ja) | 1998-06-20 | 2002-06-25 | ワシントン・ユニバーシティ | 医用画像解析、診断および治療のための膜透過性ペプチド錯体 |
| EP1102785B1 (en) | 1999-06-07 | 2013-02-13 | Arrowhead Research Corporation | COMPOSITIONS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US20020009786A1 (en) | 2000-04-18 | 2002-01-24 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US6737247B2 (en) | 2000-10-19 | 2004-05-18 | The General Hospital Corporation | Imaging of enzymatic activity |
| US7179784B2 (en) | 2001-07-10 | 2007-02-20 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
| US20050042034A1 (en) | 2003-03-27 | 2005-02-24 | Longhorn Partners Pipeline, Lp | Pipeline trench system and method of encasing for spill containment |
| WO2005019247A2 (en) | 2003-08-15 | 2005-03-03 | Board Of Regents, The University Of Texas System | Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy |
| US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
| US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| CA2583389A1 (en) | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
| SG188143A1 (en) | 2008-02-08 | 2013-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
| TW201004647A (en) | 2008-05-20 | 2010-02-01 | Sigma Tau Ind Farmaceuti | Novel dual targeting antitumoural conjugates |
| JP5539993B2 (ja) * | 2008-09-23 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 薬物送達のためのナノ担体 |
| US8278418B2 (en) * | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| KR101095841B1 (ko) | 2009-02-19 | 2011-12-21 | 주식회사 나이벡 | 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
| KR20110138246A (ko) * | 2009-03-19 | 2011-12-26 | 제너럴 일렉트릭 캄파니 | 광학 영상화제 |
| EP2429565A4 (en) | 2009-04-15 | 2012-11-14 | Univ California | NEURONIC OR NERVE PEPTIDES AND APTAMERS |
| US9682151B2 (en) | 2009-07-15 | 2017-06-20 | The Regents Of The University Of California | Peptides whose uptake in cells is controllable |
| JP5580625B2 (ja) | 2010-03-03 | 2014-08-27 | 住友化学株式会社 | メタンスルホン酸アルキルエステル溶液の製造方法 |
| JP5646923B2 (ja) | 2010-09-03 | 2014-12-24 | 矢崎総業株式会社 | 車両用表示装置及び車両用表示システム |
| CN103402546B (zh) * | 2011-02-10 | 2018-04-13 | 海德堡鲁普雷希特卡尔斯大学 | 用于肝特异性诊断的疏水性修饰肽 |
| CN103874512B (zh) * | 2011-07-29 | 2016-11-16 | 艾维拉斯生物科学公司 | 选择性递送分子及使用方法 |
| WO2014120837A2 (en) | 2013-01-29 | 2014-08-07 | The Regents Of The University Of California | Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug |
| CN105102484B (zh) | 2013-01-30 | 2020-03-10 | 艾维拉斯生物科学公司 | 选择性递送分子及使用方法 |
| EP2988786A4 (en) | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE |
-
2014
- 2014-01-30 CN CN201480019153.9A patent/CN105102484B/zh not_active Expired - Fee Related
- 2014-01-30 HK HK16105781.4A patent/HK1217720A1/zh unknown
- 2014-01-30 EA EA201591284A patent/EA031930B1/ru unknown
- 2014-01-30 KR KR1020157022729A patent/KR102278630B1/ko not_active Expired - Fee Related
- 2014-01-30 CA CA2899448A patent/CA2899448C/en active Active
- 2014-01-30 JP JP2015556140A patent/JP6508781B2/ja not_active Expired - Fee Related
- 2014-01-30 US US14/764,681 patent/US9782498B2/en not_active Expired - Fee Related
- 2014-01-30 AU AU2014212308A patent/AU2014212308B2/en not_active Ceased
- 2014-01-30 MX MX2015009858A patent/MX366375B/es active IP Right Grant
- 2014-01-30 CA CA3128911A patent/CA3128911C/en active Active
- 2014-01-30 WO PCT/US2014/013942 patent/WO2014120974A1/en not_active Ceased
- 2014-01-30 EP EP14746840.9A patent/EP2951210A4/en not_active Withdrawn
- 2014-01-30 KR KR1020217021841A patent/KR102363779B1/ko not_active Expired - Fee Related
-
2017
- 2017-08-24 US US15/685,942 patent/US10226539B2/en active Active
-
2019
- 2019-01-31 US US16/264,296 patent/US11052160B2/en not_active Expired - Fee Related
-
2021
- 2021-05-03 US US17/302,453 patent/US20220257800A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591284A1 (ru) | 2016-04-29 |
| KR20150111963A (ko) | 2015-10-06 |
| KR102278630B1 (ko) | 2021-07-16 |
| CA3128911A1 (en) | 2014-08-07 |
| CA2899448C (en) | 2021-10-26 |
| KR20210090739A (ko) | 2021-07-20 |
| CA2899448A1 (en) | 2014-08-07 |
| CN105102484B (zh) | 2020-03-10 |
| KR102363779B1 (ko) | 2022-02-15 |
| EP2951210A1 (en) | 2015-12-09 |
| EP2951210A4 (en) | 2016-09-21 |
| US20150359908A1 (en) | 2015-12-17 |
| HK1217720A1 (zh) | 2017-01-20 |
| AU2014212308A1 (en) | 2015-08-13 |
| AU2014212308B2 (en) | 2018-08-09 |
| US11052160B2 (en) | 2021-07-06 |
| CN105102484A (zh) | 2015-11-25 |
| US9782498B2 (en) | 2017-10-10 |
| WO2014120974A1 (en) | 2014-08-07 |
| JP6508781B2 (ja) | 2019-05-08 |
| US10226539B2 (en) | 2019-03-12 |
| MX2015009858A (es) | 2016-02-16 |
| EA031930B1 (ru) | 2019-03-29 |
| US20220257800A1 (en) | 2022-08-18 |
| JP2016516000A (ja) | 2016-06-02 |
| CA3128911C (en) | 2023-10-17 |
| US20190151481A1 (en) | 2019-05-23 |
| US20180000971A1 (en) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015009858A (es) | Moleculas de administracion selectiva y metodos de uso. | |
| WO2013019681A3 (en) | Selective delivery molecules and methods of use | |
| WO2012092336A3 (en) | Molecular profiling for cancer | |
| WO2014089241A3 (en) | Molecular profiling for cancer | |
| PH12018500719A1 (en) | Oligonucleotide compositions and methods thereof | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| CY1120560T1 (el) | Βελτιστοποιημενο συστημα παραδοσης in vivo me ενδοσωματολυτικους παραγοντες για συζευγματα νουκλεϊνικου οξεος | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| MY177989A (en) | Lna oligonucleotide carbohydrate conjugates | |
| WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
| EA201490559A1 (ru) | Композиция для лечения свища | |
| MX363726B (es) | Acido ribonucleico mensajero 124 como biomarcador. | |
| PH12018502731A1 (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| MX367210B (es) | Soluciones orales estables para api combinados. | |
| MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
| GB201804331D0 (en) | Catalyst article for use in an emission treatment system | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| BR112013015969A2 (pt) | câmara para um sistema de tratamento de sangue, uso da câmara, sistema de tubagem de sangue e sistema de tratamento de sangue. | |
| FR2967054B1 (fr) | Systeme conservateur | |
| EA201690445A1 (ru) | Лечение рака | |
| MX2012012978A (es) | Metodo para producir pleurodesis. | |
| PH12013500126A1 (en) | Pharmaceutical depot for 5-fluoro-2 [ [ (1s) -1- (5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile | |
| UA62955U (ru) | Применение экстракта коры осины в качестве средства адаптогенного действия | |
| IN2014DN00168A (enExample) | ||
| IN2013CH02927A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |